Sugar Editorial Picks
Jun 15, 2007 -
The NewYorkTimes.com recently had a fascinating article about how running has taken on a whole new light these days. Instead of just strapping on a pair of sneaks and hitting the sidewalk, runners are looking for more these days. From Chi Running to running camps, if you are looking to learn how to really run, it can be done.
- 5 Comments
Other Search Results
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Prognosis
- Risk Factors
- Symptoms
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Health care providers need to carefully observe patients for 2 hours after they receive an omalizumab injection. However, because an allergic reaction can occur up to 24 hours after the injection, patients need to know the signs and symptoms of anaphylaxis and how to self-administer emergency treatment.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Prognosis
- Risk Factors
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks.
- 0 Comments